ArticleNature communications2026
iEVIP: a dual-inspired intelligent platform for smart response extracellular vesicle isolation and single-vesicle profiling.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- iEVIP: a dual-inspired intelligent platform for smart response extracellular vesicle isolation and single-vesicle profiling.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Extracellular vesicles (EVs) are promising non-invasive biomarkers for early cancer detection, yet clinical translation is limited by membrane fouling during isolation and vesicle aggregation during single-vesicle imaging. Here, iEVIP (intelligent extracellular vesicle isolation and profiling), an integrated dual-inspired platform, combines intelligent pulsatile filtration, blood-smear-inspired nanoscale organization and machine-learning-based classification. Real-time transmembrane-pressure monitoring triggers back-aspiration pulses upon membrane fouling, promoting membrane regeneration and stable EV recovery from plasma. A wettability-assisted nano-smear array reduces aggregation and fluorescence overlap, enabling high-throughput multiplexed single-EV imaging. iEVIP achieves 95.32% classification accuracy for cell-line-derived EVs and up to 80.37% in exploratory clinical cohorts using random forest algorithm. By bridging macroscopic engineering principles with nanoscale bioanalysis, iEVIP provides a scalable framework for high-throughput single-EV analysis and exploratory clinical sample classification. However, the limited cohort size and absence of cross-center external validation constrain generalizability, and larger independent cohorts are needed to establish diagnostic robustness and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.